BMS's Yervoy gets EU first-line nod, Cimzia, Votuba also expanded
This article was originally published in Scrip
Bristol-Myers Squibb's Yervoy (ipilimumab) looks set to become officially available soon in Europe for previously untreated advanced melanoma patients, after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approving an extension to the drug's marketing authorization.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.